Corporate digest
Add BT as a preferred sourceLonza Group
CHEMICALS and biotech company Lonza Group will buy a sterile drug product fill-and-finish facility in Stein, Switzerland, from Novartis. Lonza, which has a secondary listing on the Singapore Exchange, said it had entered into a binding contractual commitment for the acquisition, but did not disclose the purchase price.
It will use the facility to manufacture drug products for Novartis, as well as to provide production capacity for its additional customers.
TRENDING NOW
Taiwan’s wealthy seeks diversification to Singapore, sparking private banking race: Bloomberg
Palm oil stocks set to surge as Indonesia said to be scaling back export overhaul: analysts
Serenity Park condo owners lower asking price to S$440 million in second shot at collective sale
Malaysian tycoon Vincent Tan’s sell-downs point to pruning rather than an exit plan
